Gene · 2248
Papers2,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Solitary Median Maxillary Central Incisor in Hartsfield Syndrome: A Case Report. | Int J Clin Pediatr Dent | 2023 | 37020764 | PubTator, text mining | PubMed |
| Association of microRNA gene polymorphisms with recurrent spontaneous abortion: An updated meta‑analysis. | Exp Ther Med | 2023 | 37006879 | PubTator, text mining | PubMed |
| Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. | JAMA Netw Open | 2023 | 36995716 | PubTator, text mining | PubMed |
| The unfolding story of dying tumor cells during cancer treatment. | Front Immunol | 2023 | 36993986 | PubTator, text mining | PubMed |
| Genome-Wide Identification and Characterization of Bovine Fibroblast Growth Factor (FGF) Gene and Its Expression during Adipocyte Differentiation. | Int J Mol Sci | 2023 | 36982739 | PubTator, text mining | PubMed |
| SDHA Germline Mutations in SDH-Deficient GISTs: A Current Update. | Genes (Basel) | 2023 | 36980917 | PubTator, text mining | PubMed |
| Childhood Hearing Impairment in Senegal. | Genes (Basel) | 2023 | 36980833 | PubTator, text mining | PubMed |
| Molecular Alterations in Cutaneous Squamous Cell Carcinoma in Immunocompetent and Immunosuppressed Hosts-A Systematic Review. | Cancers (Basel) | 2023 | 36980718 | PubTator, text mining | PubMed |
| Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy. | Cancers (Basel) | 2023 | 36980613 | PubTator, text mining | PubMed |
| Rps14 upregulation promotes inner ear progenitor proliferation and hair cell regeneration in the neonatal mouse cochlea. | Cell Prolif | 2023 | 36977657 | PubTator, text mining | PubMed |
| M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study. | Front Oncol | 2023 | 36969032 | PubTator, text mining | PubMed |
| Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. | Mol Cancer | 2023 | 36966334 | PubTator, text mining | PubMed |
| The Glioma-IRE project - Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach. | J Transl Med | 2023 | 36959606 | PubTator, text mining | PubMed |
Identification of a homozygous frameshift mutation in the FGF3 gene in a consanguineous Iranian family: First report of labyrinthine aplasia, microtia, and microdontia syndrome in Iran and literature review. | Mol Genet Genomic Med | 2023 | 36934406 | PubTator, text mining | PubMed |
| Differential regulation of skeletal stem/progenitor cells in distinct skeletal compartments. | Front Physiol | 2023 | 36926193 | PubTator, text mining | PubMed |
| Theoretical study on the mechanism of water oxidation catalyzed by a mononuclear copper complex: important roles of a redox non-innocent ligand and HPO4 2- anion. | RSC Adv | 2023 | 36926005 | PubTator, text mining | PubMed |
| Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital. | Front Oncol | 2023 | 36923436 | PubTator, text mining | PubMed |
| Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. | Orphanet J Rare Dis | 2023 | 36922864 | PubTator, text mining | PubMed |
| Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene. | Front Oncol | 2023 | 36910630 | PubTator, text mining | PubMed |
| Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. | Cancers (Basel) | 2023 | 36900375 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2248/papers?page=12